The increase in price target by Rosenblatt suggests a positive outlook on Adtran's valuation, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see significant momentum or changes in fundamentals that would justify a more bullish stance. Investors may view the raised target as a modestly positive signal.